PRINCETON, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences:
Live webcasts for each of the conferences will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for at least 90 days thereafter.
About Certara
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,300 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries.
Investor Relations Contact:
David Deuchler
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Daniel Yunger
Kekst CNC
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$11.02 |
| Daily Change: | 0.05 0.46 |
| Daily Volume: | 1,148,777 |
| Market Cap: | US$1.770B |
August 06, 2025 August 04, 2025 July 31, 2025 May 05, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
